Drugs / CD19/BCMA CAR-T cell therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06349343 | Feb 2025 → Jan 2026 overdue | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR-T cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06349343 ↗ |
| Modality | Cell therapy | “CD19/BCMA CAR-T cell therapy” NCT06349343 ↗ |
| Route | Intravenous | “CD19/BCMA CAR-T cell will be infused intravenously” NCT06349343 ↗ |
| Target | CD19 | “CD19/BCMA CAR-T cell therapy” NCT06349343 ↗ |